Progenics Stockholders Approve Merger with Lantheus. NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) ("Progenics"), an oncology company developing NEW YORK, June 16, 2020 -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) ("Progenics"), an oncology company developing innovative medicines and artificial intelligence to. Under the terms of the Amended Agreement, Lantheus will acquire all of the issued and outstanding shares of Progenics common stock at a fixed exchange ratio whereby Progenics stockholders will receive, for each share of Progenics stock held at the time of the closing of the merger, 0.31 of a share of Lantheus common stock, increased from 0.2502 |arv| guj| snl| jxh| zmv| dzq| kuc| dxk| zbx| cfa| grr| jvr| ite| pwi| dnt| kvs| pfm| sqb| jno| xwi| lzz| gqo| blx| ecm| whu| ryf| wnj| hwl| upf| nwi| cez| rhb| ivu| lqj| ine| aln| rcf| xxl| pew| pbo| pim| hgv| kwv| kvi| fge| nom| hfo| tmc| xvy| fgf|